(Q41175515)

English

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.

scientific article published on 23 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Young-Suk Lim

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Byung Chul Yoo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kwan Soo Byun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

So Young Kwon

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Han Chu Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yung Sang Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

0 references

publication date

23 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

65

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1042-1051

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Management of treatment failure in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Selection of chronic hepatitis B therapy with high barrier to resistance

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308435

21 January 2018

Identifiers

10.1136/GUTJNL-2014-308435

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25800784%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41175515&oldid=1590452745"